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Objectives
At the conclusion of this session, the participant will 
be able to:
 Describe Diagnostic and Statistical Manual of Mental 
Disorders, Fifth Edition (DSM-5) assessment criteria for opioid 
use disorder.
 Discuss the evidence for opioid use disorder medication-
assisted treatment.
 List types of medications and settings used in medication-
assisted therapy.
 Review considerations for buprenorphine, methadone, and 
naltrexone use for opioid use disorder.
 Outline the opioid taper process used when opioid harms 
exceed opioid benefits but opioid use disorder DSM-5 criteria 
are not met.
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Evidence
• Prevalence of DSM-IV opioid dependence in primary 
care settings among patients with chronic pain on 
opioid therapy: 3%–26% 
• Opioid agonist treatment prevents relapse 
– Methadone (full opioid agonist)
– Buprenorphine (partial opioid agonist)
• Naltrexone (opioid antagonist) can be effective in 
patients who are able to continue treatment
Treat patients for opioid 
use disorder (OUD) if needed
• Clinicians should offer or arrange evidence-based 
treatment (usually medication-assisted treatment with 
buprenorphine or methadone in combination with 
behavioral therapies) for patients with opioid use disorder. 
(Recommendation category A: Evidence type: 2)
Opioid use disorder
• Previously classified as opioid abuse or opioid 
dependence (DSM-IV)
• Defined in DSM-5 as a problematic pattern of opioid 
use leading to clinically significant impairment or 
distress 
– manifested by at least two defined criteria 
– occurring within a year
Opioid Use Disorder diagnostic criteria 
[first 9 of 11 criteria]
A problematic pattern of opioid use leading to clinically significant impairment or distress, as 
manifested by at least two of the following, occurring within a 12-month period:
1. Opioids are often taken in larger amounts or over a longer period than was intended.
2. There is a persistent desire or unsuccessful efforts to cut down or control opioid use.
3. A great deal of time is spent in activities necessary to obtain the opioid, use the opioid, or 
recover from its effects.
4. Craving, or a strong desire or urge to use opioids.
5. Recurrent opioid use resulting in a failure to fulfill major role obligations at work, school, or 
home.
6. Continued opioid use despite having persistent or recurrent social or interpersonal problems 
caused or exacerbated by the effects of opioids.
7. Important social, occupational, or recreational activities are given up or reduced because of 
opioid use.
8. Recurrent opioid use in situations in which it is physically hazardous.
9. Continued opioid use despite knowledge of having a persistent or recurrent physical or 
psychological problem that is likely to have been caused or exacerbated by the substance.
From http://pcssmat.org/wp-content/uploads/2014/02/5B-DSM-5-Opioid-Use-Disorder-Diagnostic-Criteria.pdf
Opioid Use Disorder diagnostic criteria
[last 2 of 11 criteria]
A problematic pattern of opioid use leading to clinically significant impairment or distress, as 
manifested by at least two of the following, occurring within a 12-month period:
10. Tolerance, as defined by either of the following:
a. A need for markedly increased amounts of opioids to achieve intoxication or desired 
effect.
b. A markedly diminished effect with continued use of the same amount of an opioid.
Note: This criterion is not considered to be met for those taking opioids solely under appropriate 
medical supervision.
11. Withdrawal, as manifested by either of the following:
a. The characteristic opioid withdrawal syndrome (refer to Criteria A and B of the criteria set 
for opioid withdrawal).
b. Opioids (or a closely related substance) are taken to relieve or avoid withdrawal 
symptoms.
Note: This criterion is not considered to be met for those individuals taking opioids solely
under appropriate medical supervision.
From http://pcssmat.org/wp-content/uploads/2014/02/5B-DSM-5-Opioid-Use-Disorder-Diagnostic-Criteria.pdf
If you suspect opioid use disorder
• Discuss your concern with your patient 
• Provide an opportunity for your patient to disclose 
related concerns or problems
• Assess for opioid use disorder 
– Use DSM-5 criteria or 
– Arrange for assessment with a substance use 
disorder specialist
• Do not dismiss patients from care—use the 
opportunity to provide potentially lifesaving 
information and interventions
If patient meets criteria for opioid use disorder, 
offer or arrange evidence-based treatment
• Treat with medication-assisted treatment 
(buprenorphine or naltrexone)
or
• Arrange for medication-assisted treatment from an 
– Office-based provider (buprenorphine or naltrexone)
or
– Opioid treatment program (buprenorphine or 
methadone maintenance therapy)
Buprenorphine (partial opioid agonist)
• Can be prescribed/dispensed for opioid use disorder by 
qualified clinicians with a DATA waiver
• Sublingual, buccal forms available with or without naloxone
• Initiate when patient in mild-moderate opioid withdrawal
• Most patients stabilized on 8 to 16 mg/day
– MME thresholds in the CDC Guideline for Prescribing 
Opioids for Chronic Pain are NOT applicable to opioid 
agonist treatment of opioid use disorder
• Needs to be tapered gradually when discontinued
Methadone (long-acting opioid agonist)
• For treatment of opioid use disorder, can only be 
dispensed by an opioid treatment program (OTP)
• Patients need to go to OTP for methadone
– usually daily early in therapy
– limited use of take-home doses
• Length of time in methadone treatment 
– minimum of 12 months recommended
– patients may require treatment for years
– If stopped, must be gradual to prevent withdrawal
Naltrexone (opioid antagonist)
• Blocks effects of opioids if used--causes immediate withdrawal
– Use only in nonpregnant adults
– Do not start if patient is taking or recently took opioids 
or has signs of withdrawal
– Start 3-10 days after last use (longer if longer-acting opioids)
• Most effective in closely supervised patients
• Naltrexone dosing forms for opioid dependence: 
– Oral tablet (daily) 
– Long-acting injectable naltrexone (every 4 weeks IM)
Resources for treatment
• SAMHSA’s buprenorphine physician locator 
(http://buprenorphine.samhsa.gov/bwns_locator)
• SAMHSA’s Opioid Treatment Program Directory 
(http://dpt2.samhsa.gov/treatment/directory.aspx)
• SAMHSA’s Provider Clinical Support System for Opioid 
Therapies (http://pcss-o.org) 
• SAMHSA’s Provider’s Clinical Support System for 
Medication-Assisted Treatment (http://pcssmat.org)
• HHS Treatment & Recovery Resources: 
(http://www.hhs.gov/opioids/treatment-and-recovery/)
Free electronic resources from SAMHSA at  
http://store.samhsa.gov/
• Medication-Assisted Treatment of Opioid Use Disorder 
Pocket Guide
• Advisory: Sublingual and Transmucosal Buprenorphine 
for Opioid Use Disorder: Review and Update
• Clinical Use of Extended-Release Injectable Naltrexone 
in the Treatment of Opioid Use Disorder: A Brief Guide
Resources for treatment
• MATx: A mobile app from 
SAMHSA to support medication-
assisted treatment of opioid use 
disorder
• Available on Google Play and 
the App Store
Assess your community’s treatment capacity 
for opioid use disorder
• Identify treatment resources for opioid use disorder in 
your community 
• Work with other clinicians to ensure sufficient 
treatment capacity at the practice level
• Consider training and obtaining a DATA waiver that 
allows you to prescribe buprenorphine to treat patients 
with opioid use disorder
How to qualify for a waiver to prescribe 
buprenorphine
• Complete required training (8 hours) in the treatment 
and management of patients with opioid use disorders 
through ASAM, SAMHSA, or other organization
(See samhsa.gov/medication-assisted-
treatment/training-resources/buprenorphine-
physician-training)
• Apply for a waiver through SAMHSA 
(See buprenorphine.samhsa.gov)
What about problematic opioid use that does 
not meet criteria for opioid use disorder?
• Offer to taper and discontinue opioids
• For patients who choose to but are unable to taper 
– Reassess for opioid use disorder 
– Offer opioid agonist therapy if criteria are met
Connect With Us
Find more information on drug overdose and 
the Guideline:
• www.cdc.gov/drugoverdose
• www.cdc.gov/drugoverdose/prescribing/guideline.html
Are you on Twitter?
• Follow @DebHouryCDC and @CDCInjury for 
useful information and important Guideline 
updates.
Find out more about Injury Center social 
media: 
• www.cdc.gov/injury/socialmedia
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Patients with opioid use disorder
Opioid use disorder case
 Ron, a 50 year old man with a history of alcohol use 
disorder in remission and long term high dose opioid 
treatment after a work accident years ago
 Quit drinking alcohol after falling off a ladder at work 
and sustaining multiple traumatic injuries, resulting in 
high dose opioid therapy that was never tapered
 Taking morphine ER 90mg TID and short acting 
morphine 30 mg up to 4 per day 
 Total opioid dose 390mg MED
Opioid use disorder case
 Since transfer from another provider, aberrant 
behaviors have been noted:
 Urine test negative for prescribed morphine and positive 
for oxycodone. The patient admits to “borrowing” 
oxycodone from a friend after running out of medication 
due to a pain flare.
 Admits to difficulty controlling medication use when pain 
flares, resulting in withdrawal when medication runs out.
 Prescription Monitoring Program shows two additional 
prescribing physicians.  The patient denies obtaining these 
medications.
 Physically hazardous – no 
 Use despite medical or 
psychological problems – no 
 Tolerance – yes
 Withdrawal - yes
 Takes more than intended – yes
 Desire to cut down – no
 Time spent – no
 Craving – ?? (“it’s the pain”)
 Leads to role problems – “Maybe” 
 Use despite social problems – ?? (“it’s the pain”) 
 Important activities given up – ?? (It’s the pain”) 
Opioid use disorder diagnosis
Opioid use disorder diagnosis
 Presenting the diagnosis:
 “You meet the criteria for an opioid use disorder”
 “Trouble controlling the medication makes it unsafe”
 “The medicine has become a problem in itself”
 Discussing treatment options
 “Continuing the current treatment is not safe, but you do 
need opioid medication for the use disorder”
 “Stabilizing the brain with medication can help a lot”
 “Other kinds of pain treatments will work better if the brain 
is more stable”
Helping patients accept the 
diagnosis
 “All kinds of people have opioid use disorder”
 “I don’t see it as a bad person doing a bad thing”
 “Sometimes the medications cause problems due to 
genetic factors that we cannot anticipate”
 “Getting help for this should be like getting help for any 
other chronic medical problem”
Opioid use disorder treatment:
buprenorphine/naloxone
 Usually recommended as first medication option –
fewer barriers to treatment
 Far safer than high dose opioids for pain
 Effective no matter how high the prescribed opioid 
dose
 Ideally provided by the same physician (so get trained!)
 Insurance coverage for use disorder, not for pain
 Butrans patch is approved for pain, not opioid use 
disorder, and doses are much lower than for use 
disorder
Opioid use disorder treatment: 
methadone maintenance
 Most effective treatment in retaining patients
 Higher barrier to treatment
 Must coach patients to seek addiction treatment rather 
than pain management
 Provides maximum structure for patients with more 
severe psychosocial challenges 
 Discuss take-home dose opportunities
What about high dose prescribed 
methadone?
 Methadone has long-acting metabolites that increase 
the risk of precipitated withdrawal when starting 
buprenorphine
 Tapering to 30-40 mg daily increases risk of withdrawal 
and illicit opioid use
 Higher dose prescribed methadone patients will likely 
require transfer to methadone maintenance
 Can offer to continue prescription pending transfer, but 
may require coerced transfer (transfer or taper)
Conclusions
 Opioid use disorder diagnoses can be difficult in the 
setting of long-term opioid prescribing
 Pharmacotherapy is the most important aspect of 
effective opioid use disorder treatment
 Obtaining a waiver to prescribe buprenorphine is an 
important management tool when there is co-
occurring opioid use disorder and chronic pain
 Facilitating OUD treatment requires effective patient 
communication
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What about problematic opioid use 
that does not meet criteria for OUD?
 Suzanne, 46 yr old woman with chronic neck pain 
following “whiplash” injury during a motor vehicle crash  
5 years earlier
 She has been on opioids for these 5 years, prescribed 
by a colleague of yours that has recently retired
 Her opioid dose has gradually escalated due to 
requests, pain “flare-ups”, and other minor MVAs
 She is currently taking ER oxycodone 40mg BID, plus 
oxycodone 5mg for breakthrough pain, up to 5/day 
 Total opioid dose 157.5mg MED
Case of problematic opioid use
Case of problematic opioid use  
the good news
 She has no history of illicit drug use and her UDTs have 
not shown any illicit drugs
 She has not sought out multiple prescribers for her 
opioids nor has she been going to the ED for extra 
doses, this is confirmed by consulting the state 
Prescription Drug Monitoring Program (PDMP)
 She had some early refill requests years ago, but your 
colleague told her these were not allowed and she has 
made no further requests
Case of problematic opioid use   
the bad news
 She now reports that her pain intensity is 8/10, pain interference with 
general activities is 7/10, and pain interference with enjoyment of 
life is 9/10. She is asking for an increase in her oxycodone
 HER OPIOID THERAPY IS NOT WORKING
 She is 5’4”, 245lb, and her husband complains of her snoring
 SHE LIKELY HAS SLEEP APNEA
 She smokes cigarettes, about 1PPD for 25 years
 AS A SMOKER, SHE IS AT HIGH RISK FOR BAD OPIOID OUTCOMES
 She takes alprazolam 1mg PRN for panic attacks
 OPIOIDS PLUS BENZODIAZEPINES GREATLY INCREASE RISK OF FATAL OD
Opioid taper is appropriate for this 
patient
 After 5 years of opioid therapy, she is not doing well.   
Her pain scores are high and she is seeking more 
opioids.
 She is at high risk for serious adverse events due to likely 
sleep apnea, tobacco use, benzodiazepine use
 These risks will decrease with opioid dose reduction
 Her pain level may not increase with opioid dose 
reduction and may decrease
Introducing opioid taper to the 
patient
 Explain that you can see that her opioid therapy is not
working and that she is at high risk for bad events. These 
will not get better with further dose increases, but may 
get better with opioid dose decrease.
 It is usually better to introduce the idea of opioid taper 
at the visit before the visit when you start the taper.
 Pledge that you will not abandon the patient and that 
you will make sure that she has adequate pain relief.
 Patients are afraid of overwhelming pain or withdrawal 
and need to be reassured this will not happen.
Negotiating opioid taper with the 
patient
 It is always best to get the patient to agree to try taper.
 Tell the patient that there is no need to rush the taper. 
She can decide to pause the taper at any point. But 
once the taper starts, opioid doses will not be 
increased.
 Allow her to choose whether long-acting or short-acting 
opioids are tapered first. Most patients choose to taper 
long-acting first. She can also be offered the choice of 
tapering her benzodiazepine first.
 You might begin with a taper of 10% of the original 
dose per month, but this can be negotiated.
Making opioid taper a success for 
both prescriber and patient
 Explore her own ambivalence about opioid therapy. 
What concerns does she have about opioids? (PODS)
 Monitor depression, anxiety and insomnia before and 
during taper. If these are controlled, pain does not 
usually increase. You may need to start or adjust 
antidepressant medication.
 Offer the patient pain self-management resources
 Referral
 Books
 Websites 
Conclusions
 Opioid taper is appropriate for patients without OUD 
whose opioid therapy has low efficacy and high risks
 These patients are often ambivalent about opioid 
therapy and have their own reasons for tapering that 
can be elicited and supported
 Patients are fearful of opioid taper and need  to be 
reassured that you will not abandon them to their pain
 Attention to depression, anxiety, and insomnia is crucial 
for successful opioid taper
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